Odonate starts Phase III trial of tesetaxel to treat breast cancer

By Alicia Parker | Jan 5, 2018 | 10:52 PM GMT

Odonate Therapeutics Inc. (NASDAQ:ODT) began the Phase III CONTESSA trial of tesetaxel (DJ-927) to treat locally